{'fraction_non_alphanumeric': 0.021677662582469368, 'fraction_numerical': 0.00942507068803016, 'mean_word_length': 5.8076923076923075, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Endoscopic sclerotherapy of oesophageal varices due to hepatosplenic schistosomiasis. A randomized controlled trial evaluating effect of sclerosant concentration.

Forty consecutive patients with bleeding oesophageal varices underwent paravariceal injection with 2.5% or 5% ethanolamine oleate in a single-blind randomized controlled trial. Patients were injected on a weekly basis until varices were eradicated and then followed-up for a period of two years. Patients injected with 2.5% ethanolamine oleate experienced a significantly shorter duration of dysphagia and significantly less episodes of fever, ulceration, and luminal narrowing. Patients injected with 5% ethanolamine oleate required significantly less injection sessions to eradicate their varices. However, the probability of rebleeding was significantly lower in patients injected with 2.5% ethanolamine oleate. This study supports the use of ethanolamine in a concentration of 2.5% when injected paravariceally as it is associated with less complications and a lower probability of rebleeding.